A Phase 2 interventional study of rabeprazole sodium in Gastroesophageal Reflux Disease, sponsored by Eisai Inc.. Completed at 25 sites in United States. Open to participants aged 12 Years to 16 Years. Per ClinicalTrials.gov, last updated 2009-12-03.
Sponsored by Eisai Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing rabeprazole in Gastroesophageal Reflux — none open to participants now, none under way, none of them phase 3. Rabeprazole · Gastroesophageal Reflux.
Among the 40 studies testing rabeprazole in Gastroesophageal Reflux, this one is the 19th largest by enrollment of the 39 interventional ones that give a count, is one of 7 that started in 2005, is one of 4 in phase 2, and was the 1st registered.
1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.
Browse Gastroesophageal Reflux studies →None of the 40 studies testing rabeprazole in Gastroesophageal Reflux is open now. The open studies under Gastroesophageal Reflux, anywhere →
Rabeprazole: first FDA approval 1999 (ACIPHEX). What it is approved for, and how studies give it, is on its page →
Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.
This study: 12 Years to 16 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 5 · Phase 3 17 · Phase 4 8
First in 2001; this study’s year is marked. 7 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 111 is above the median of 68 across 799 interventional studies indexed under Gastroesophageal Reflux.
Median enrollment 100 across the 39 interventional studies. Of the 38 that completed or were terminated, 15 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 40 have an industry lead sponsor. The 10 most frequent:
This study is registered under Eisai Inc., one of the names counted as Eisai Co., Ltd.. Under that name alone:
Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
13 studies in Gastroesophageal Reflux by Eisai Co., Ltd.: none open now, none under way, none of them phase 3. Of 13 finished, 12 (92%) have results posted.
Among the 13 studies in Gastroesophageal Reflux by Eisai Co., Ltd., this one is the 11th largest by enrollment, is one of 2 that started in 2005, is one of 2 in phase 2, and was the 1st registered.
Eisai Co., Ltd.’s Gastroesophageal Reflux studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 40 studies testing rabeprazole in Gastroesophageal Reflux, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eisai Co., Ltd.’s 13 in Gastroesophageal Reflux:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to collect safety information on rabeprazole 10 mg and 20 mg in the treatment of gastroesophageal reflux disease (GERD) in children aged 12 to 16 years. The secondary objectives are to assess the efficacy of rabeprazole on the improvement of the symptoms of GERD and to explore the relationship of symptom relief to dose received, based on symptom frequency and severity, antacid use, and quality of life (QOL) measures.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
administered orally and once daily to patients randomized to receive either 10 mg or 20 mg.
Treatment-emergent Adverse Events Experienced by >=5% of Patients in Any Treatment Group
Primary safety outcomes include adverse events, physical examinations and clinical laboratory results. AE results are presented in the table.
Time frame: 8 weeks from randomization and end of treatment
This study was recruited at 25 centers in the US during the period of 18-Aug-2005 and 1-May-2006.
| Milestone | Rabeprazole 10 mg | Rabeprazole 20 mg |
|---|---|---|
| Started | 54 | 57 |
| Completed | 52 | 55 |
| Not completed | 2 | 2 |
| Withdrew: Withdrawal by subject | 1 | 2 |
| Withdrew: Physician decision | 1 | 0 |
Primary safety outcomes include adverse events, physical examinations and clinical laboratory results. AE results are presented in the table.
| Participants | Rabeprazole 10 mg | Rabeprazole 20 mg |
|---|---|---|
| Diarrhea | 3 | 2 |
| Nausea | 3 | 2 |
| Upper abdominal pain | 1 | 3 |
| Chest pain | 0 | 3 |
| Upper respiratory tract infection | 4 | 3 |
| Bronchitis | 3 | 2 |
| Pharyngitis | 3 | 2 |
| Sinusitis | 2 | 3 |
| Nasopharyngitis | 1 | 4 |
| Otitis media | 1 | 3 |
| Headache | 5 | 6 |
| Pharyngolaryngeal pain | 6 | 5 |
| Cough | 5 | 3 |
| Nasal congestion | 4 | 4 |
| Total # subjects reporting AEs | 41 | 45 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rabeprazole 10 mg | — | — | — |
| Rabeprazole 20 mg | — | — | — |
| Event | Rabeprazole 10 mg | Rabeprazole 20 mg |
|---|---|---|
| Mood swingsNervous system disorders | 0/54 | 1/57 |
| Event | Rabeprazole 10 mg | Rabeprazole 20 mg |
|---|---|---|
| Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders | 6/54 | 5/57 |
| HeadacheNervous system disorders | 5/54 | 6/57 |
| CoughRespiratory, thoracic and mediastinal disorders | 5/54 | 3/57 |
| Upper respiratory tract infectionInfections and infestations | 4/54 | 3/57 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 4/54 | 4/57 |
| NasopharyngitisInfections and infestations | 1/54 | 4/57 |
| DiarrheaGastrointestinal disorders | 3/54 | 2/57 |
| NauseaGastrointestinal disorders | 3/54 | 2/57 |
| BronchitisInfections and infestations | 3/54 | 2/57 |
| PharyngitisInfections and infestations | 3/54 | 2/57 |
| Age Continuous(years) | Rabeprazole 10 mg | Rabeprazole 20 mg | Total |
|---|---|---|---|
| Mean | 14.2 ± 1.3 | 14.1 ± 1.5 | 14.2 ± 1.4 |
| Sex: Female, Male(Participants) | Rabeprazole 10 mg | Rabeprazole 20 mg | Total |
|---|---|---|---|
| Female | 27 | 26 | 53 |
| Male | 27 | 31 | 58 |
| Race/Ethnicity, Customized(participants) | Rabeprazole 10 mg | Rabeprazole 20 mg | Total |
|---|---|---|---|
| Asian | 0 | 0 | 0 |
| Black or African American | 4 | 1 | 5 |
| White | 47 | 53 | 100 |
| Hispanic | 1 | 2 | 3 |
| Other | 2 | 1 | 3 |
| Region of Enrollment(participants) | Rabeprazole 10 mg | Rabeprazole 20 mg | Total |
|---|---|---|---|
| United States | 54 | 57 | 111 |
The record gives a start of Aug 2005, a primary completion of May 2006 and a completion of Jul 2006. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2009, 3 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rabeprazole